← Leaderboards
Danielle Smith
Roswell Park Cancer Institute Corp
$1,360,269
Attributed
$2,720,537
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $706.2K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,720,537 · 1
By mechanism
R01$2,720,537 · 1
Top collaborators
- Maciej Lukasz Goniewicz4 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Kenneth Michael Cummings$7,969,251
- Andrew Hyland$4,344,561
- Maciej Lukasz Goniewicz$7,908,117
Others in their field
Other Rising Stars on “Acute”
- Taleen Hanania · Psychogenics, Inc.$9,482,040
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Christopher J. Lindsell · Vanderbilt University Medical Center$8,536,327
- Michael E. Roth · Public Health Institute$8,201,777
- Jacob Sutton Coverstone · Neurovations$6,882,205
- Agustin G Yip · Albert Einstein College Of Medicine$6,090,308
Research focus
AcuteBehaviorAppearanceBehavior InfluenceCannabinoidsCannabisBehavior AssessmentCharacteristicsClinical Trials DesignDesignDevice DesignsDevicesDoseDouble-Blind MethodDrug Delivery SystemsDrug KineticsElectronic CigaretteElementsEvaluationEvidence BaseFutureGenerationsHeatingHuman Data
Grant awards (4)
Assessing pharmacokinetic and pharmacodynamic variability of Î9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine$651,235
R01 · FY2025 · DA · contact PI
Assessing pharmacokinetic and pharmacodynamic variability of Î9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine$666,413
R01 · FY2024 · DA · contact PI
Assessing pharmacokinetic and pharmacodynamic variability of Î9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine$696,738
R01 · FY2023 · DA · contact PI
Assessing pharmacokinetic and pharmacodynamic variability of Î9-tetrahydrocannabinol delivered from vaping products with and without concurrent use of nicotine$706,151
R01 · FY2022 · DA · contact PI